Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2031

Conditions

Phase 1Recurrent MelanomaRefractory Melanoma

Interventions

DRUG

Cyclophosphamide

Given by IV

DRUG

Fludarabine

Given by IV

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER